OCEANSIDE, CA--(Marketwired - Feb 3, 2015) - Therapeutic Solutions International, Inc. (
As previously announced on December 10, 2014 in a Form 8-K filing with the SEC the Company entered into a Material Definitive Agreement, the Company acquired: (i) by assignment, all of Innovative Supplements, Inc.'s contractual right, title and interest in and to proprietary formulations for two nutritional supplement products known under the trade names: (a) "T-Rx™"; and, (b) "Vital Female™; and, (ii) by purchase, all legal right, title and interest, in and to intellectual property including, but not limited to, Innovative's nutritional supplement product known under the trade name: "ProJuvenol™." The Company is developing a new Corporate and e-commerce website and plans their launch as soon as the work is completed.
ProJuvenol™ is a powerful synergistic blend of complex anti-aging ingredients inspired by nature to help promote cellular rejuvenation and healthy functionality for everyday living, based upon pterostilbene, one of nature's unique and intelligent antioxidants/anti-inflammatories. ProJuvenol includes a scientifically valid blend of interactive ingredients with anti-aging and cellular protective properties to help support optimal health and provide the benefits of mental alertness and physical well-being.
T-Rx™ is formulated to assist in increasing your testosterone levels. The result is an increase in testosterone levels, which assist in adding lean muscle mass, bone density, increased energy and the reduction of fat.
Vital™ is designed for women to increase energy, increase bone density, reduce fat and improve muscle tone. Additionally Vital will optimize hormone levels increase libido and decrease symptoms of stress and anxiety.
Tim Dixon, President & CEO stated, "TSI's overall business plan is twofold; first, to produce and refine currently owned products or those under license agreements, also, to develop and manufacture for sale an innovative retail line of Nutraceutical products, dietary supplements and related products, and second, to market those products aggressively in various media including the Internet, Social Media and Television advertisements."
Additionally, as previously announced on October 2, 2014 in a Form 8-K filing with the SEC the Company reported, a former employee of the Company, Reid Jilek, sued the Company, its two directors and its three officers in San Diego County (California) Superior Court for breach of contract, retaliation, constructive discharge, failure to pay wages, failure to reimburse, conversion and fraudulent inducement. The complaint related to his employment agreement with the Company and his resignation which was effective in January 2013. The trial was held in September 2014. On September 26, 2014 the Court ruled in favor of the Company and against all of Jilek's claims, and ruled that the Company was the prevailing party, and therefore was entitled to recover its attorney's fees and costs from Jilek. The Company did not prevail in its cross-claims against Jilek. Jilek's claims against the Company's directors and officers had previously been dismissed. On January 30, 2015 the Court granted an award for Attorney's fee in the amount of $145,000.
Mr. Dixon concluded: "We will continue to work hard to build our company and both our Board of Directors and Management thank our shareholders for their ongoing support and belief in our company."
About Therapeutic Solutions International, Inc. Supplement Division
The Company's corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed at www.projuvenol.com. These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at www.sec.gov.
Contact Information:
For more information please contact:
Therapeutic Solutions International, Inc.
ir@tsoimail.com